Seppo Ylä‐Herttuala

Author

Seppo Ylä‐Herttuala

Also Known As

&NA; YLÄ-HERTTUALA, &NA; Ylä-Herttuala, Daniela Schott, H REIJONEN, John Martin, S Bhardwaj, S YLAHERTTUALA, S Yla-Herttuala, S Ylä-Herttuala, S. Herttuala

1.1K

Publications

61.6K

Citations

127

H-Index

296

Concepts

All Affiliations

University of Eastern Finland Kuopio University Hospital University of Helsinki Turku University Hospital

About

Seppo Ylä‐Herttuala is an author at University of Eastern Finland specializing in medicine, vascular biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	81	223	30K
2	Health Sciences	29	41	7.3K
3	Engineering	17	18	1.1K
4	Natural Sciences	13	14	1.1K
5	Public Health	6	6	344

Seppo Ylä‐Herttuala

507

Publications

51.2K

Citations

118

H-Index

Page 1

	Year	Citations
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Seppo Ylä‐Herttuala, Wulf Palinski, Michael E. Rosenfeld, Journal of Clinical Investigation Vascular DiseasePathologyHyperlipidemiaLow DensityOxidative Stress	1989	1.9K
Low density lipoprotein undergoes oxidative modification in vivo. Wulf Palinski, Michael E. Rosenfeld, Seppo Ylä‐Herttuala, Proceedings of the National Academy of Sciences InflammationMetabolic SyndromeLow Density LipoproteinBiochemistryAtherosclerosis	1989	1.5K
Autoantibody against oxidised LDL and progression of carotid atherosclerosis J T Salonen, H Korpela, R. Salonen, The Lancet Metabolic SyndromeThrombosisVascular DiseaseCardiovascular DiseasePhysiology	1992	1.3K
Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Seppo Ylä‐Herttuala, Beth Lipton, Michael E. Rosenfeld, Proceedings of the National Academy of Sciences Vascular DiseaseImmunologyPathologyCellular PhysiologyInflammation	1991	877
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation Tuomas Tammela, Georgia Zarkada, Elisabet Wallgard, Nature Vascular Network FormationAngiogenesisVascular BiologyNeovascularizationVascular Endothelial Growth Factor	2008	799
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 Taija Mäkinen, Lotta Jussila, Tanja Veikkola, Nature Medicine AngiogenesisAutoimmune DiseaseSoluble Vegf Receptor-3ImmunologyLymphatic System	2001	767
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Terhi Kärpänen, Mikala Egeblad, Marika J. Karkkainen, Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) ImmunologyPathologyTumor LymphangiogenesisTumor BiologyTumor Angiogenesis	2001	653
Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Wulf Palinski, Seppo Ylä‐Herttuala, Michael E. Rosenfeld, Arteriosclerosis An Official Journal of the American Heart Association Inc InflammationLow Density LipoproteinOxysterolBiochemistryLipid Peroxidation	1990	614
A model for gene therapy of human hereditary lymphedema Marika J. Karkkainen, Anne Saaristo, Lotta Jussila, Proceedings of the National Academy of Sciences Human GrowthImmunologyPathologyBiological TherapyDermatology	2001	604
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis Tatiana V. Petrova, Terhi Kärpänen, Camilla Norrmén, Nature Medicine Defective ValvesImmunologyPathologyLymphatic SystemLymphatic Disease	2004	587

Page 1